<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-10708-2016019 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">HIV envelope trimer vaccines that engage desirable germline antibodies</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">Despite 30 years of intensive research, an effective HIV-1 vaccine remains elusive. One of the major challenges is the induction of broadly neutralizing antibodies (bNAbs) by envelope glycoprotein (Env) based vaccines</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Despite 30 years of intensive research, an effective HIV-1 vaccine remains elusive. One of the major challenges is the induction of broadly neutralizing antibodies (bNAbs) by envelope glycoprotein (Env) based vaccines. Since 2009 a wealth of new bNAbs have been identified that can be used as templates for vaccine design. However, there is accumulating evidence that HIV-1 Env vaccines generally are not able to bind to the unmutated germline ancestors of these bNAbs, which may be the reason that these vaccines are not able to induce similar types of bNAbs. Here we propose to generate Env trimer vaccines specifically designed to bind to the unmutated germline ancestors of known human bNAbs. We have 3 approaches to achieve this goal. 1. A patient-based approach: by screening early Env sequences from patients from the Amsterdan Cohort that developed bNAbs. 2. A structure-based approach: by computationally designing Env surfaces that are able to bind unmutated germline ancestors of bNAbs. 3. A library screening approach: by screening randomly generated variant Env trimers, displayed on the surface of mammalian cells, by FACS. Collectively, these approaches should allow us to generate Env vaccines that are more efficient in generating bNAbs.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Here we propose to generate Env trimer vaccines specifically designed to bind to the unmutated germline ancestors of known human bNAbs. We have 3 approaches to achieve this goal. 1. A patient-based approach: by screening early Env sequences from patients from the Amsterdan Cohort that developed bNAbs. 2. A structure-based approach: by computationally designing Env surfaces that are able to bind unmutated germline ancestors of bNAbs. 3. A library screening approach: by screening randomly generated variant Env trimers, displayed on the surface of mammalian cells, by FACS. Collectively, these approaches should allow us to generate Env vaccines that are more efficient in generating bNAbs.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientific community
People at risk for HIV</narrative>
  </description>
  <participating-org ref="NL-KVK-34362777" role="4" type="80">
   <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-10-01" type="1"></activity-date>
  <activity-date iso-date="2019-11-01" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <location>
   <name>
    <narrative xml:lang="EN">Amsterdam</narrative>
   </name>
  </location>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">HIV envelope trimer vaccines that engage desirable germline antibodies STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2016-10-01"></period-start>
   <period-end iso-date="2019-11-01"></period-end>
   <value currency="EUR" value-date="2016-10-01">262663</value>
  </budget>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-10-28"></transaction-date>
   <value currency="EUR" value-date="2016-10-28">70000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-12-28"></transaction-date>
   <value currency="EUR" value-date="2017-12-28">70000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-28"></transaction-date>
   <value currency="EUR" value-date="2017-12-28">70000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-09-12"></transaction-date>
   <value currency="EUR" value-date="2020-09-12">122663</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-09-13"></transaction-date>
   <value currency="EUR" value-date="2020-09-13">122663</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-10-26"></transaction-date>
   <value currency="EUR" value-date="2016-10-26">70000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-41204333">
    <narrative xml:lang="EN">AMR Amsterdam</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
